The EGFR TKI erlotinib and EGFR neutralizing antibodies (cetuximab and panitumumab) all showed only minimal or nearly no significant improvement in patient survival when combining them respectively with chemotherapy compared to chemotherapy alone.[10, 11, 12] Till now, it remains unclear whether certain molecular subtypes of iCCA patients might benefit from clinical EGFR‐targeted therapy. The gene discussed is EGFR; the disease is infantile convulsions and choreoathetosis.